**Part I: Tuberculosis (TB) Screening Questionnaire** (to be completed by incoming students)

Please answer the following questions:

Have you ever had close contact with persons known or suspected to have active TB disease?  

Were you born in one of the countries or territories listed below that have a high incidence of active TB disease? (If yes, please CIRCLE the country, below)

<table>
<thead>
<tr>
<th>Country</th>
<th>Country</th>
<th>Country</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afghanistan</td>
<td>Congo</td>
<td>Iran (Islamic Republic of)</td>
<td>Namibia</td>
</tr>
<tr>
<td>Algeria</td>
<td>Côte d'Ivoire</td>
<td>Iraq</td>
<td>Singapore</td>
</tr>
<tr>
<td>Angola</td>
<td>Democratic People's Republic of Kazakhstan</td>
<td>Kuwait</td>
<td>Solomon Islands</td>
</tr>
<tr>
<td>Anguilla</td>
<td>Democratic Republic of Korea</td>
<td>Kyrgyzstan</td>
<td>Somalia South Africa</td>
</tr>
<tr>
<td>Argentina</td>
<td>Congo</td>
<td>Lao People's Democratic Republic</td>
<td>South Sudan</td>
</tr>
<tr>
<td>Armenia</td>
<td>Djibouti</td>
<td>Latvia</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td>Azerbaijan</td>
<td>Dominican Republic</td>
<td>Lesotho</td>
<td>Sudan</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>Ecuador</td>
<td>Liberia</td>
<td>Suriname</td>
</tr>
<tr>
<td>Belarus</td>
<td>El Salvador</td>
<td>Libya</td>
<td>Swaziland</td>
</tr>
<tr>
<td>Belize</td>
<td>Equatorial Guinea</td>
<td>Lithuania</td>
<td>Tanzania</td>
</tr>
<tr>
<td>Benin</td>
<td>Eritrea</td>
<td>Madagascar</td>
<td>Tuvalu</td>
</tr>
<tr>
<td>Bhutan</td>
<td>Estonia</td>
<td>Malawi</td>
<td>Turkmenistan</td>
</tr>
<tr>
<td>Bolivia (Plurinational State of)</td>
<td>Ethiopia</td>
<td>Malaysia</td>
<td>Uganda</td>
</tr>
<tr>
<td>Bosnia and Herzegovina</td>
<td>Fiji</td>
<td>Maldives</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Botswana</td>
<td>French Polynesia</td>
<td>Mali</td>
<td>United Republic of Tanzania</td>
</tr>
<tr>
<td>Brazil</td>
<td>Gabon</td>
<td>Marshall Islands</td>
<td>United States</td>
</tr>
<tr>
<td>Brunei Darussalam</td>
<td>Gambia</td>
<td>Mauritania</td>
<td>Uruguay</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>Georgia</td>
<td>Mauritius</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>Ghana</td>
<td>Mauritius</td>
<td>Vanuatu</td>
</tr>
<tr>
<td>Burundi</td>
<td>Greenland</td>
<td>Mexico</td>
<td>Venzuela (Bolivarian Republic of)</td>
</tr>
<tr>
<td>Cabo Verde</td>
<td>Guam</td>
<td>Micronesia (Federated States of)</td>
<td>Vietnam</td>
</tr>
<tr>
<td>Cambodia</td>
<td>Guatemala</td>
<td>Mongolia</td>
<td>Viet Nam</td>
</tr>
<tr>
<td>Cameroon</td>
<td>Guinea-Bissau</td>
<td>Montenegro</td>
<td>Yemen</td>
</tr>
<tr>
<td>Central African Republic</td>
<td>Haiti</td>
<td>Morocco</td>
<td>Zambia</td>
</tr>
<tr>
<td>Chad</td>
<td>Guyana</td>
<td>Mozambique</td>
<td>Zimbabwe</td>
</tr>
<tr>
<td>China</td>
<td>Guinea</td>
<td>Myanmar</td>
<td></td>
</tr>
<tr>
<td>China, Hong Kong SAR</td>
<td>Honduras</td>
<td></td>
<td></td>
</tr>
<tr>
<td>China, Macao SAR</td>
<td>India</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colombia</td>
<td>Indonesia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Have you had frequent or prolonged visits* to one or more of the countries or territories listed above with a high prevalence of TB disease? (If yes, CHECK the countries or territories, above)

Have you been a resident and/or employee of high-risk congregate settings (e.g., correctional facilities, long-term care facilities, and homeless shelters)?

Have you been a volunteer or health care worker who served clients who are at increased risk for active TB disease?

Have you ever been a member of any of the following groups that may have an increased incidence of latent *M. tuberculosis* infection or active TB disease: medically underserved, low-income, or abusing drugs or alcohol?

If the answer is YES to any of the above questions, ONU Health Center requires that you see a health care provider to complete Part II and Part III for assessment and TB testing prior to arriving on campus.

If the answer to all of the above questions is NO, no further testing or further action is required. Please sign this page and submit to ONU Health Center address or fax. (See address and fax above)

Student Name: ____________________________ DOB __________ Date: __________
**Part II. Clinical Assessment by Health Care Provider**

Clinicians should review and verify the information in Part I. Persons answering YES to any of the questions in Part I are candidates for either Mantoux tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA), unless a previous positive test has been documented.

History of a positive TB skin test or IGRA blood test? (If yes, document below) **Yes ____ No ____**

History of BCG vaccination? (If yes, consider IGRA if possible.) **Yes ____ No ____

1. **TB Symptom Check**

   **Does the student have signs or symptoms of active pulmonary tuberculosis disease?**  **Yes ____ No ____**

   If No, proceed to 2 or 3

   **If yes, check below:**
   - Cough (especially if lasting for 3 weeks or longer) with or without sputum production
   - Coughing up blood (hemoptysis)
   - Chest pain
   - Loss of appetite
   - Unexplained weight loss
   - Night sweats
   - Fever

   Proceed with additional evaluation to exclude active tuberculosis disease including tuberculin skin testing, chest x-ray, and sputum evaluation as indicated.

2. **Tuberculin Skin Test (TST)**

   (TST result should be recorded as actual millimeters (mm) of induration, transverse diameter; if no induration, write “0”. The TST interpretation should be based on mm of induration as well as risk factors.)**

   **Date Given:** ___/___/___  **Date Read:** ___/___/___

   **Result:** _____ mm of induration  **Interpretation:** positive____ negative____

   **Date Given:** ___/___/___  **Date Read:** ___/___/___

   **Result:** _____ mm of induration  **Interpretation:** positive____ negative____

   **Interpretation guidelines**

   **>5 mm is positive:**
   - Recent close contacts of an individual with infectious TB
   - Persons with fibrotic changes on a prior chest x-ray, consistent with past TB disease
   - Organ transplant recipients and other immunosuppressed persons (including receiving equivalent of >15 mg/d of prednisone for >1 month.)
   - HIV-infected persons

   **>10 mm is positive:**
   - Recent arrivals to the U.S. (<5 years) from high prevalence areas or who resided in one for a significant* amount of time
   - Injection drug users
   - Mycobacteriology laboratory personnel
   - Residents, employees, or volunteers in high-risk congregate settings
   - Persons with medical conditions that increase the risk of progression to TB disease including silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (leukemias and lymphomas, cancers of the head, neck, or lung), gastrectomy or jejunoileal bypass and weight loss of at least 10% below ideal body weight.

   **>15 mm is positive:**
   - Persons with no known risk factors for TB who, except for certain testing programs required by law or regulation, would otherwise not be tested.

*The significance of the travel exposure should be discussed with a health care provider and evaluated.*
3. Interferon Gamma Release Assay (IGRA)

Date Obtained: ____/____/____ (specify method) QFT-GIT T-Spot other____

M  D  Y

Result: negative__  positive__  indeterminate__  borderline__ (T-Spot only)

Date Obtained: ____/____/____ (specify method) QFT-GIT T-Spot other____

M  D  Y

Result: negative__  positive__  indeterminate__  borderline__ (T-Spot only)

4. Chest x-ray: (Required if TST or IGRA is positive)

Date of chest x-ray: ____/____/____  Result: normal__  abnormal__

M  D  Y

Part III. Management of Positive TST or IGRA

All students with a positive TST or IGRA with no signs of active disease on chest x-ray should receive a recommendation to be treated for latent TB with appropriate medication. However, students in the following groups are at increased risk of progression from LTBI to TB disease and should be prioritized to begin treatment as soon as possible.

- Infected with HIV
- Recently infected with M. tuberculosis (within the past 2 years)
- History of untreated or inadequately treated TB disease, including persons with fibrotic changes on chest radiograph consistent with prior TB disease
- Receiving immunosuppressive therapy such as tumor necrosis factor-alpha (TNF) antagonists, systemic corticosteroids equivalent to/greater than 15 mg of prednisone per day, or immunosuppressive drug therapy following organ transplantation
- Diagnosed with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, neck, or lung
- Have had a gastrectomy or jejunoleal bypass
- Weigh less than 90% of their ideal body weight
- Cigarette smokers and persons who abuse drugs and/or alcohol

Populations defined locally as having an increased incidence of disease due to M. tuberculosis, including medically underserved, low-income populations

_____  Student agrees to receive treatment

_____  Student declines treatment at this time

____________________________________________________          ______________________________
Health Care Professional Signature  Date

_______________________________________________________________
Address

Ohio Northern University (ONU) Health Center
525 S. Main Street Ada, Ohio 45810
Phone 419-772-2086   Fax 419 772-2545   health-center@onu.edu

Prepared originally by ACHA’s Tuberculosis Guidelines Task Force
Revised by Emerging Public Health Threats and Emergency Response Coalition April 2016 and ONU Health Center 04/28/17